There is no recent news confirming a deal between BioMarin Pharmaceutical Inc. and Inozyme Pharma, Inc. However, attention around BioMarin remains high with Leerink Partners, now known as SVB Securities, maintaining a positive outlook on the company's financial performance. In February 2025, Leerink Partners notably increased their earnings projection for BioMarin's second quarter, raising the expected earnings per share from $0.81 to $0.94, demonstrating confidence in the company's growth trajectory.
Amidst this backdrop, BioMarin continues to engage actively with investors, having participated in significant events such as the Leerink Partners Global BioPharma Conference in March 2024. These engagements underscore BioMarin's strategy of keeping the investment community informed and highlight its commitment to transparency and growth.
In contrast, Inozyme Pharma has been prioritizing its ENPP1 Deficiency pivotal program, reaching a key milestone with the completion of enrollment for its ENERGY 3 trial by January 2025. This focus highlights Inozyme's strategic efforts to advance its clinical programs, potentially showcasing the company's dedication to its niche specialization in rare disease therapies.